A recombinant construct comprises a scaffold portion and at least two species of epitope capable of eliciting anti-arteriosclerotic vascular disease responses via at least two independent pathways, for use in the treatment or prevention of atherosclerosis. Preferably at least one epitope is derived from either complement C5a protein or C5a receptor (C5aR). The second or further epitope species may be selected from heat shock protein (HSP) epitopes (preferably human HSP-60 or Mycobacterium bovis HSP-65), Chlamydia pneumonia epitopes, such as epitopes derived from major outer membrane protein (MOMP) and/or putative outer membrane protein 5 (Pomp5), protease activated receptor 1 (PAR-1) epitopes, apolipoprotein (preferably ApoB) epitopes and/or perilipin epitopes. The scaffold portion may be derived from dendroaspin. The construct may be used in vaccine compositions.
